ClinicalTrials.gg
CompletedNCT01519089Updated Aug 13, 2015Results posted

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

A Phase 3 interventional study of CP-690,550 and CP-690, 550 in Psoriasis, sponsored by Pfizer. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-13.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's title name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.

Enrollment
7th of 10
95 · median 237
Started
2012
the only one that year
Phase 3
7 of 10
1 open now
Registered
1st of 10
by date
Lead sponsor
5 of 10
Pfizer

Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 7th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 1st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing tofacitinib in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment.

03

Conditions studied

  • Psoriasis

Keywords

  • chronic
  • severe
  • moderate
  • treatment
  • safety
  • efficacy
  • CP-690
  • 550
  • Plaque psoriasis
  • Psoriasis Vulgaris
  • Psoriatic Arthritis
  • tofacitinib
  • Xeljanz
04

In context

Arthritis, Psoriatic Reclassified

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's enrollment of 95 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 20 years or older and considered to be candidates for systemic or phototherapy.

[Moderate to Severe Plaque Psoriasis]

  • Diagnosed for at least 12 months.
  • Have Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis covering at least 10% of body surface area (BSA).

[Psoriatic Arthritis]

  • Diagnosed for at least 6 months.
  • Meet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at screening;
  • Have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and active plaque psoriasis with at least 2 cm in diameter.

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug induced forms of psoriasis
  • Cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic arthritis or cannot discontinue phototherapy (PUVA or UVB)
  • any uncontrolled significant medical condition
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    CP-690,550 10 mg BID

    Drug: CP-690,550

  • Experimental
    CP690,550 5 mg BID

    Drug: CP-690, 550

Interventions

  • 10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.

  • 5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.

    Time frame: Week 16

  2. Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 16

  3. Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

    ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

    Time frame: Week 16

  4. Number of Participants With Adjudicated Cardiovacular Events

    Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.

    Time frame: Baseline to Follow-up

  5. Number of Participants With Malignancy Events _Week 0 Through Follow-up

    For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.

    Time frame: Baseline to Follow-up

Secondary outcomes

  1. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.

    Time frame: Week 2, 4, 8, 12, 20, 28, 40, 52

  2. Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  3. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  4. Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Week 16

  5. Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Week 16

  6. Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Week 16

  7. Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Week 16

  8. Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  9. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  10. Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  11. Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 2, 4, 8, 12, 20, 28, 40, 52

  12. Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  13. Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.

    Time frame: Week 20, 28, 40, 52

  14. Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.

    Time frame: Week 20, 28, 40, 52

  15. Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.

    Time frame: Week 8, 16, 20, 28, 40, 52

  16. Number of Affected Nails

    Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.

    Time frame: Baseline, Week 8, 16, 20, 28, 40, 52

  17. Itch Severity Item (ISI) Score

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  18. Dermatology Life Quality Index (DLQI) Score

    The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  19. Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score

    36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

    Time frame: Week (W) 16, 28, 52

  20. Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score

    36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

    Time frame: Week 16, 28, 52

  21. Work Limitation Questionnaire (WLQ)

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).

    Time frame: Baseline (BL), Week (W) 4, 16, 28, 52

  22. Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).

    Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  23. Joint Pain Assessment (JPA)

    The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain."

    Time frame: Baseline, Week 4, 16, 28, 52

  24. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response

    ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

    Time frame: Week 2, 4, 8, 12, 20, 28, 40, 52

  25. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response

    ACR50 response: greater than or equal to (\>=) 50 percent (%) improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  26. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response

    ACR70 response: greater than or equal to (\>=) 70 percent (%) improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  27. Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count

    Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  28. Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count

    Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  29. Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain

    Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  30. Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis

    Subjects answered the following question, "Considering the possible effects of the arthritis, how are you feeling today?" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  31. Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis

    The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  32. Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)

    The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

  33. Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

    Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

08

Results

Posted Aug 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneCP-690,550 5 mg BIDCP-690,550 10 mg BID
Started4748
Received treatment4747
Completed4033
Not completed715
Withdrew: Adverse event44
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject02
Withdrew: Other26
Withdrew: Not received study drug01

Outcome measures

PrimaryPercentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 1662.872.767.8
PrimaryPercentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 1667.468.267.8
PrimaryProportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16100100100
PrimaryNumber of Participants With Adjudicated Cardiovacular Events

Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.

Time frame:
Baseline to Follow-up
Reported as:
Number · Participants
Number of Participants With Adjudicated Cardiovacular Events
ParticipantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Number of Participants With Adjudicated Cardiovacular Events000
PrimaryNumber of Participants With Malignancy Events _Week 0 Through Follow-up

For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.

Time frame:
Baseline to Follow-up
Reported as:
Number · Participants
Number of Participants With Malignancy Events _Week 0 Through Follow-up
ParticipantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Number of participants with any malignancy events000
Malignancy excluding non-melanoma skin cancer000
Lymphoma/Lymphoproliferative disorders (LPD)000
Melanoma000
Non-melanoma skin cancer000
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.

Time frame:
Week 2, 4, 8, 12, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 22.34.53.4
Week 47.022.714.9
Week 841.954.548.3
Week 1260.570.565.5
Week 2067.463.665.5
Week 2869.865.967.8
Week 4069.863.666.7
Week 5262.863.663.2
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 29.322.716.1
Week 434.956.846.0
Week 860.581.871.3
Week 1281.484.182.8
Week 1676.779.578.2
Week 2079.175.077.0
Week 2890.772.781.6
Week 4088.479.583.9
Week 5290.768.279.3
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 20.00.00.0
Week 44.713.69.2
Week 816.329.523.0
Week 1237.245.541.4
Week 1637.254.546.0
Week 2058.156.857.5
Week 2855.845.550.6
Week 4058.147.752.9
Week 5251.247.749.4
SecondaryTime to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Week 16
Reported as:
Median · Week
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
WeekCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'8.0 (8.0 to 12.0)8.0 (4.0 to 12.0)8.0 (NA to NA)
SecondaryTime to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Week 16
Reported as:
Median · Week
Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response
WeekCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response12.0 (8.0 to 16.0)8.0 (8.0 to 12.0)12.0 (8.0 to 12.0)
SecondaryTime to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Week 16
Reported as:
Median · Week
Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response
WeekCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response8.0 (4.0 to 12.0)4.0 (4.0 to 8.0)8.0 (4.0 to 8.0)
SecondaryTime to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Week 16
Reported as:
Median · Week
Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response
WeekCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) ResponseNA (12.0 to NA)12.0 (12.0 to 16.0)16.0 (12.0 to NA)
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 22.30.01.1
Week 40.02.31.1
Week 8 (n=43, 41, 84)0.00.00.0
Week 12 (n=43, 41, 84)0.02.41.2
Week 16 (n=43, 40, 83)0.02.51.2
Week 20 (n=43, 39, 82)0.00.00.0
Week 28 (n=43, 39, 82)0.00.00.0
Week 40 (n=41, 38, 79)0.00.00.0
Week 52 (n=39, 32, 71)0.00.00.0
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-5.18 ± 5.898-7.36 ± 6.428-6.28 ± 6.232
Week 4-10.40 ± 7.518-13.16 ± 8.739-11.79 ± 8.229
Week 8 (n=43, 41, 84)-15.95 ± 8.392-19.90 ± 10.741-17.88 ± 9.756
Week 12 (n=43, 41, 84)-18.91 ± 8.918-21.68 ± 11.598-20.26 ± 10.344
Week 16 (n=43, 40, 83)-19.53 ± 9.094-22.06 ± 12.606-20.75 ± 10.935
Week 20 (n=43, 39, 82)-20.95 ± 9.239-22.18 ± 12.045-21.53 ± 10.617
Week 28 (n=43, 39, 82)-21.77 ± 10.196-21.46 ± 10.503-21.62 ± 10.280
Week 40 (n=41, 38, 79)-22.20 ± 10.181-21.18 ± 10.229-21.71 ± 10.151
Week 52 (n=39, 32, 71)-21.96 ± 9.621-22.11 ± 10.598-22.03 ± 10.000
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Component Score

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2: Erythema (Head/Neck)-0.5 ± 0.83-0.9 ± 0.82-0.7 ± 0.84
Week 2: Erythema (Upper Limbs)-0.5 ± 0.67-0.8 ± 0.72-0.6 ± 0.70
Week 2: Erythema (Trunk)-0.6 ± 0.67-0.8 ± 0.69-0.7 ± 0.69
Week 2: Erythema (Lower Limbs)-0.7 ± 0.69-0.8 ± 0.71-0.7 ± 0.70
Week 2: Induration (Head/Neck)-0.4 ± 0.70-0.8 ± 0.89-0.6 ± 0.82
Week 2: Induration (Upper Limbs)-0.5 ± 0.63-0.6 ± 0.75-0.6 ± 0.69
Week 2: Induration (Trunk)-0.5 ± 0.63-0.7 ± 0.59-0.6 ± 0.62
Week 2: Induration (Lower Limbs)-0.5 ± 0.67-0.7 ± 0.71-0.6 ± 0.69
Week 2: Scaling (Head/Neck)-0.4 ± 0.66-0.9 ± 0.91-0.7 ± 0.83
Week 2: Scaling (Upper Limbs)-0.4 ± 0.59-0.8 ± 0.74-0.6 ± 0.69
Week 2: Scaling (Trunk)-0.3 ± 0.57-0.8 ± 0.76-0.6 ± 0.71
Week 2: Scaling (Lower Limbs)-0.4 ± 0.70-0.7 ± 0.73-0.6 ± 0.73
Week 4: Erythema (Head/Neck)-0.8 ± 1.02-1.3 ± 0.99-1.0 ± 1.02
Week 4: Erythema (Upper Limbs)-1.1 ± 0.81-1.2 ± 0.94-1.1 ± 0.87
Week 4: Erythema (Trunk)-1.0 ± 0.64-1.3 ± 0.79-1.1 ± 0.72
Week 4: Erythema (Lower Limbs)-1.1 ± 0.91-1.2 ± 0.79-1.2 ± 0.85
Week 4: Induration (Head/Neck)-0.7 ± 0.89-1.2 ± 1.09-1.0 ± 1.02
Week 4: Induration (Upper Limbs)-1.1 ± 0.86-1.0 ± 0.85-1.0 ± 0.85
Week 4: Induration (Trunk)-0.9 ± 0.80-1.3 ± 0.82-1.1 ± 0.83
Week 4: Induration (Lower Limbs)-1.0 ± 0.90-1.2 ± 0.98-1.1 ± 0.94
Week 4: Scaling (Head/Neck)-0.8 ± 0.86-1.2 ± 0.99-1.0 ± 0.95
Week 4: Scaling (Upper Limbs)-0.9 ± 0.70-1.2 ± 0.86-1.0 ± 0.79
Week 4: Scaling (Trunk)-0.9 ± 0.71-1.3 ± 0.95-1.1 ± 0.87
Week 4: Scaling (Lower Limbs)-0.8 ± 0.72-1.3 ± 0.96-1.1 ± 0.89
Week 8: Erythema (Head/Neck) (n=43, 41, 84)-1.4 ± 1.13-1.6 ± 1.03-1.5 ± 1.08
Week 8: Erythema (Upper Limbs) (n=43, 41, 84)-1.5 ± 0.93-1.6 ± 0.98-1.5 ± 0.95
Week 8: Erythema (Trunk) (n=43, 41, 84)-1.7 ± 0.91-1.9 ± 0.93-1.8 ± 0.92
Week 8: Erythema (Lower Limbs) (n=43, 41, 84)-1.5 ± 0.91-1.7 ± 0.91-1.6 ± 0.91
Week 8: Induration (Head/Neck) (n=43, 41, 84)-1.3 ± 0.91-1.6 ± 1.10-1.4 ± 1.01
Week 8: Induration (Upper Limbs) (n=43, 41, 84)-1.6 ± 0.93-1.6 ± 0.89-1.6 ± 0.91
Week 8: Induration (Trunk) (n=43, 41, 84)-1.6 ± 0.98-1.7 ± 1.03-1.7 ± 1.00
Week 8: Induration (Lower Limbs) (n=43, 41, 84)-1.6 ± 0.91-1.7 ± 0.98-1.7 ± 0.94
Week 8: Scaling (Head/Neck) (n=43, 41, 84)-1.3 ± 0.90-1.5 ± 1.03-1.4 ± 0.96
Week 8: Scaling (Upper Limbs) (n=43, 41, 84)-1.3 ± 0.80-1.6 ± 0.86-1.5 ± 0.84
Week 8: Scaling (Trunk) (n=43, 41, 84)-1.4 ± 0.82-1.8 ± 1.00-1.6 ± 0.93
Week 8: Scaling (Lower Limbs) (n=43, 41, 84)-1.3 ± 0.82-1.8 ± 0.88-1.5 ± 0.88
Week 12: Erythema (Head/Neck) (n=43, 41, 84)-1.7 ± 1.10-1.7 ± 0.98-1.7 ± 1.04
Week 12: Erythema (Upper Limbs) (n=43, 41, 84)-1.9 ± 0.99-1.8 ± 1.13-1.8 ± 1.05
Week 12: Erythema (Trunk) (n=43, 41, 84)-2.1 ± 1.08-2.0 ± 0.95-2.0 ± 1.01
Week 12: Erythema (Lower Limbs) (n=43, 41, 84)-1.9 ± 0.92-1.9 ± 0.94-1.9 ± 0.92
Week 12: Induration (Head/Neck) (n=43, 41, 84)-1.5 ± 0.94-1.6 ± 1.12-1.6 ± 1.02
Week 12: Induration (Upper Limbs) (n=43, 41, 84)-1.7 ± 0.94-1.8 ± 0.99-1.7 ± 0.96
Week 12: Induration (Trunk) (n=43, 41, 84)-2.0 ± 1.01-2.0 ± 1.00-2.0 ± 1.00
Week 12: Induration (Lower Limbs) (n=43, 41, 84)-1.9 ± 0.91-1.9 ± 1.06-1.9 ± 0.98
Week 12: Scaling (Head/Neck) (n=43, 41, 84)-1.7 ± 0.92-1.6 ± 1.02-1.6 ± 0.96
Week 12: Scaling (Upper Limbs) (n=43, 41, 84)-1.4 ± 0.91-1.7 ± 0.95-1.6 ± 0.94
Week 12: Scaling (Trunk) (n=43, 41, 84)-1.6 ± 1.05-1.9 ± 1.00-1.7 ± 1.03
Week 12: Scaling (Lower Limbs) (n=43, 41, 84)-1.5 ± 0.85-1.9 ± 1.00-1.7 ± 0.95
Week 16: Erythema (Head/Neck) (n=43, 40, 83)-1.7 ± 1.14-1.7 ± 1.07-1.7 ± 1.10
Week 16: Erythema (Upper Limbs) (n=43, 40, 83)-1.9 ± 1.13-1.9 ± 1.12-1.9 ± 1.12
Week 16: Erythema (Trunk) (n=43, 40, 83)-2.1 ± 1.10-2.0 ± 1.07-2.0 ± 1.08
Week 16: Erythema (Lower Limbs) (n=43, 40, 83)-2.0 ± 1.03-1.9 ± 0.94-2.0 ± 0.99
Week 16: Induration (Head/Neck) (n=43, 40, 83)-1.5 ± 0.96-1.6 ± 1.17-1.6 ± 1.06
Week 16: Induration (Upper Limbs) (n=43, 40, 83)-1.8 ± 0.96-1.8 ± 1.01-1.8 ± 0.98
Week 16: Induration (Trunk) (n=43, 40, 83)-2.1 ± 1.01-2.0 ± 1.01-2.0 ± 1.01
Week 16: Induration (Lower Limbs) (n=43, 40, 83)-2.1 ± 0.95-2.0 ± 1.08-2.0 ± 1.01
Week 16: Scaling (Head/Neck) (n=43, 40, 83)-1.6 ± 0.95-1.6 ± 1.08-1.6 ± 1.01
Week 16: Scaling (Upper Limbs) (n=43, 40, 83)-1.5 ± 0.93-1.7 ± 1.05-1.6 ± 0.99
Week 16: Scaling (Trunk) (n=43, 40, 83)-1.6 ± 0.96-1.8 ± 1.09-1.7 ± 1.02
Week 16: Scaling (Lower Limbs) (n=43, 40, 83)-1.6 ± 0.93-1.8 ± 1.06-1.7 ± 1.00
Week 20: Erythema (Head/Neck) (n=43, 39, 82)-1.8 ± 1.15-1.6 ± 0.96-1.7 ± 1.07
Week 20: Erythema (Upper Limbs) (n=43, 39, 82)-1.9 ± 0.97-1.9 ± 1.26-1.9 ± 1.11
Week 20: Erythema (Trunk) (n=43, 39, 82)-2.2 ± 1.04-2.1 ± 1.04-2.1 ± 1.04
Week 20: Erythema (Lower Limbs) (n=43, 39, 82)-2.1 ± 1.04-2.1 ± 1.09-2.1 ± 1.05
Week 20: Induration (Head/Neck) (n=43, 39, 82)-1.6 ± 1.00-1.5 ± 1.12-1.6 ± 1.06
Week 20: Induration (Upper Limbs) (n=43, 39, 82)-1.9 ± 0.97-1.7 ± 1.14-1.8 ± 1.05
Week 20: Induration (Trunk) (n=43, 39, 82)-2.1 ± 1.01-1.9 ± 1.07-2.0 ± 1.04
Week 20: Induration (Lower Limbs) (n=43, 39, 82)-2.2 ± 0.95-2.0 ± 1.06-2.1 ± 1.00
Week 20: Scaling (Head/Neck) (n=43, 39, 82)-1.7 ± 0.94-1.5 ± 1.05-1.6 ± 0.99
Week 20: Scaling (Upper Limbs) (n=43, 39, 82)-1.5 ± 0.96-1.6 ± 1.14-1.5 ± 1.04
Week 20: Scaling (Trunk) (n=43, 39, 82)-1.7 ± 0.93-1.8 ± 1.05-1.8 ± 0.99
Week 20: Scaling (Lower Limbs) (n=43, 39, 82)-1.7 ± 0.92-1.8 ± 1.16-1.8 ± 1.04
Week 28: Erythema (Head/Neck) (n=43, 39, 82)-1.8 ± 1.11-1.6 ± 0.81-1.7 ± 0.98
Week 28: Erythema (Upper Limbs) (n=43, 39, 82)-2.1 ± 1.09-1.8 ± 1.07-2.0 ± 1.08
Week 28: Erythema (Trunk) (n=43, 39, 82)-2.1 ± 1.13-2.0 ± 0.99-2.1 ± 1.06
Week 28: Erythema (Lower Limbs) (n=43, 39, 82)-2.3 ± 1.05-1.9 ± 0.99-2.1 ± 1.03
Week 28: Induration (Head/Neck) (n=43, 39, 82)-1.7 ± 0.97-1.6 ± 0.99-1.6 ± 0.98
Week 28: Induration (Upper Limbs) (n=43, 39, 82)-2.0 ± 1.12-1.7 ± 1.10-1.9 ± 1.12
Week 28: Induration (Trunk) (n=43, 39, 82)-2.0 ± 1.12-1.8 ± 1.16-1.9 ± 1.14
Week 28: Induration (Lower Limbs) (n=43, 39, 82)-2.2 ± 1.03-1.8 ± 1.14-2.0 ± 1.09
Week 28: Scaling (Head/Neck) (n=43, 39, 82)-1.7 ± 1.01-1.4 ± 1.07-1.6 ± 1.04
Week 28: Scaling (Upper Limbs) (n=43, 39, 82)-1.8 ± 1.05-1.6 ± 1.02-1.7 ± 1.03
Week 28: Scaling (Trunk) (n=43, 39, 82)-1.7 ± 0.99-1.8 ± 1.11-1.7 ± 1.05
Week 28: Scaling (Lower Limbs) (n=43, 39, 82)-1.8 ± 1.09-1.7 ± 1.02-1.7 ± 1.05
Week 40: Erythema (Head/Neck) (n=41, 38, 79)-1.9 ± 1.10-1.7 ± 0.90-1.8 ± 1.01
Week 40: Erythema (Upper Limbs) (n=41, 38, 79)-2.1 ± 1.05-1.9 ± 1.06-2.0 ± 1.06
Week 40: Erythema (Trunk) (n=41, 38, 79)-2.1 ± 1.04-2.2 ± 0.87-2.2 ± 0.95
Week 40: Erythema (Lower Limbs) (n=41, 38, 79)-2.4 ± 1.05-2.0 ± 1.03-2.2 ± 1.05
Week 40: Induration (Head/Neck) (n=41, 38, 79)-1.7 ± 1.05-1.5 ± 1.08-1.6 ± 1.07
Week 40: Induration (Upper Limbs) (n=41, 38, 79)-2.0 ± 1.18-1.8 ± 0.98-1.9 ± 1.09
Week 40: Induration (Trunk) (n=41, 38, 79)-1.9 ± 1.26-2.1 ± 0.93-2.1 ± 1.11
Week 40: Induration (Lower Limbs) (n=41, 38, 79)-2.2 ± 1.14-1.9 ± 1.03-2.1 ± 1.10
Week 40: Scaling (Head/Neck) (n=41, 38, 79)-1.8 ± 0.97-1.4 ± 1.00-1.6 ± 0.99
Week 40: Scaling (Upper Limbs) (n=41, 38, 79)-1.7 ± 1.10-1.8 ± 0.94-1.7 ± 1.02
Week 40: Scaling (Trunk) (n=41, 38, 79)-1.7 ± 0.93-1.9 ± 1.03-1.8 ± 0.98
Week 40: Scaling (Lower Limbs) (n=41, 38, 79)-1.9 ± 1.11-1.8 ± 1.06-1.8 ± 1.08
Week 52: Erythema (Head/Neck) (n=39, 32, 71)-1.9 ± 1.17-1.6 ± 1.24-1.8 ± 1.20
Week 52: Erythema (Upper Limbs) (n=39, 32, 71)-2.0 ± 1.15-2.0 ± 0.90-2.0 ± 1.04
Week 52: Erythema (Trunk) (n=39, 32, 71)-2.2 ± 1.01-2.2 ± 0.93-2.2 ± 0.97
Week 52: Erythema (Lower Limbs) (n=39, 32, 71)-2.1 ± 1.11-2.2 ± 0.94-2.1 ± 1.03
Week 52: Induration (Head/Neck) (n=39, 32, 71)-1.7 ± 1.06-1.5 ± 1.22-1.6 ± 1.13
Week 52: Induration (Upper Limbs) (n=39, 32, 71)-1.9 ± 1.21-2.0 ± 0.97-1.9 ± 1.10
Week 52: Induration (Trunk) (n=39, 32, 71)-1.8 ± 1.39-2.1 ± 1.03-2.0 ± 1.24
Week 52: Induration (Lower Limbs) (n=39, 32, 71)-2.0 ± 1.29-2.2 ± 0.97-2.1 ± 1.15
Week 52: Scaling (Head/Neck) (n=39, 32, 71)-1.8 ± 0.98-1.6 ± 1.08-1.7 ± 1.02
Week 52: Scaling (Upper Limbs) (n=39, 32, 71)-1.6 ± 1.02-1.9 ± 0.98-1.7 ± 1.01
Week 52: Scaling (Trunk) (n=39, 32, 71)-1.6 ± 0.96-1.9 ± 1.01-1.7 ± 0.98
Week 52: Scaling (Lower Limbs) (n=39, 32, 71)-1.7 ± 1.15-2.0 ± 1.03-1.8 ± 1.10
SecondaryPercentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 2, 4, 8, 12, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 27.015.911.5
Week 430.238.634.5
Week 858.161.459.8
Week 1272.175.073.6
Week 2072.159.165.5
Week 2867.454.560.9
Week 4067.454.560.9
Week 5258.156.857.5
SecondaryPercentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2: Clear000
Week 2: Almost Clear7.015.911.5
Week 2: Mild39.543.241.4
Week 2: Moderate46.534.140.2
Week 2: Severe7.06.86.9
Week 4: Clear011.45.7
Week 4: Almost Clear30.227.328.7
Week 4: Mild44.240.942.5
Week 4: Moderate18.620.519.5
Week 4: Severe7.003.4
Week 8: Clear (n=43, 41, 84)7.026.816.7
Week 8: Almost Clear (n=43, 41, 84)51.239.045.2
Week 8: Mild (n=43, 41, 84)27.924.426.2
Week 8: Moderate (n=43, 41, 84)14.09.811.9
Week 8: Severe (n=43, 41, 84)000
Week 12: Clear (n=43, 41, 84)14.036.625.0
Week 12: Almost Clear (n=43, 41, 84)58.143.951.2
Week 12: Mild (n=43, 41, 84)20.99.815.5
Week 12: Moderate (n=43, 41, 84)7.09.88.3
Week 12: Severe (n=43, 41, 84)000
Week 16: Clear (n=43, 40, 83)27.940.033.7
Week 16: Almost Clear (n=43, 40, 83)39.535.037.3
Week 16: Mild (n=43, 40, 83)25.617.521.7
Week 16: Moderate (n=43, 40, 83)7.05.06.0
Week 16: Severe (n=43, 40, 83)02.51.2
Week 20: Clear (n=43, 39, 82)27.938.532.9
Week 20: Almost Clear (n=43, 39, 82)44.228.236.6
Week 20: Mild (n=43, 39, 82)18.625.622.0
Week 20: Moderate (n=43, 39, 82)9.37.78.5
Week 20: Severe(n=43, 39, 82)000
Week 28: Clear (n=43, 39, 82)37.233.335.4
Week 28: Almost Clear (n=43, 39, 82)30.228.229.3
Week 28: Mild (n=43, 39, 82)27.930.829.3
Week 28: Moderate (n=43, 39, 82)4.77.76.1
Week 28: Severe (n=43, 39, 82)000
Week 40: Clear (n=41, 38, 79)43.934.239.2
Week 40: Almost Clear (n=41, 38, 79)26.828.927.8
Week 40: Mild (n=41, 38, 79)24.428.926.6
Week 40: Moderate (n=41, 38, 79)4.97.96.3
Week 40: Severe (n=41, 38, 79)000
Week 52: Clear (n=39, 32, 71)41.043.842.3
Week 52: Almost Clear (n=39, 32, 71)23.134.428.2
Week 52: Mild (n=39, 32, 71)30.818.825.4
Week 52: Moderate (n=39, 32, 71)5.13.14.2
Week 52: Severe (n=39, 32, 71)000
SecondaryPercentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.

Time frame:
Week 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2096.387.591.5
Week 2892.678.184.7
Week 4081.571.976.3
Week 5270.462.566.1
SecondaryPercentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.

Time frame:
Week 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2010083.391.5
Week 2893.173.383.1
Week 4082.866.774.6
Week 5265.560.062.7
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI) Score

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.

Time frame:
Week 8, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 8 (n=32, 28, 60)-3.3 ± 9.63-1.8 ± 7.72-2.6 ± 8.75
Week 16 (n=32, 28, 60)-11.2 ± 15.27-9.4 ± 12.66-10.4 ± 14.02
Week 20 (n=32, 27, 59)-15.0 ± 15.29-14.1 ± 13.03-14.6 ± 14.18
Week 28 (n=32, 27, 59)-21.1 ± 15.83-16.4 ± 15.27-18.9 ± 15.62
Week 40 (n=31, 26, 57)-22.2 ± 16.18-16.2 ± 14.13-19.5 ± 15.45
Week 52 (n=30, 22, 52)-20.6 ± 15.16-16.2 ± 15.62-18.7 ± 15.36
SecondaryNumber of Affected Nails

Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.

Time frame:
Baseline, Week 8, 16, 20, 28, 40, 52
Reported as:
Mean · nails
Number of Affected Nails
nailsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Baseline7.94 ± 2.827.13 ± 3.077.55 ± 2.95
Week 8 (n=32, 28, 60)7.66 ± 3.177.11 ± 3.027.40 ± 3.09
Week 16 (n=32, 28, 60)6.91 ± 3.435.75 ± 3.566.37 ± 3.51
Week 20 (n=32, 27, 59)6.16 ± 3.604.59 ± 4.025.44 ± 3.85
Week 28 (n=32, 27, 59)4.53 ± 3.873.59 ± 3.964.10 ± 3.91
Week 40 (n=31, 26, 57)3.32 ± 3.943.77 ± 3.813.53 ± 3.85
Week 52 (n=30, 22, 52)3.73 ± 4.252.50 ± 3.073.21 ± 3.81
SecondaryItch Severity Item (ISI) Score

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Itch Severity Item (ISI) Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Baseline6.16 ± 2.6695.32 ± 2.9675.74 ± 2.839
Week 25.19 ± 2.7973.30 ± 2.5304.23 ± 2.815
Week 43.65 ± 2.3792.27 ± 2.4722.95 ± 2.510
Week 8 (n=43, 41, 84)2.26 ± 2.3811.22 ± 1.7391.75 ± 2.145
Week 12 (n=43, 41, 84)1.77 ± 2.3791.20 ± 1.8331.49 ± 2.137
Week 16 (n=43, 40, 83)1.67 ± 2.3780.90 ± 1.2571.30 ± 1.949
Week 20 (n=43, 39, 82)0.95 ± 1.6181.28 ± 1.5891.11 ± 1.603
Week 28 (n=43, 39, 82)1.12 ± 1.6511.62 ± 2.1961.35 ± 1.933
Week 40 (n=41, 38, 79)0.90 ± 1.8141.13 ± 1.8481.01 ± 1.822
Week 52 (n=39, 32, 71)1.15 ± 2.0840.91 ± 1.3291.04 ± 1.776
SecondaryDermatology Life Quality Index (DLQI) Score

The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Dermatology Life Quality Index (DLQI) Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Baseline11.3 ± 6.258.6 ± 5.919.9 ± 6.19
Week 27.8 ± 5.205.8 ± 5.326.8 ± 5.32
Week 4 (n=43, 43, 86)5.9 ± 5.074.2 ± 4.635.1 ± 4.90
Week 8 (n=43, 41, 84)4.0 ± 3.952.8 ± 3.303.4 ± 3.67
Week 12 (n=43, 41, 84)2.6 ± 2.861.8 ± 2.682.2 ± 2.79
Week 16 (n=43, 40, 83)2.2 ± 3.041.9 ± 2.732.1 ± 2.88
Week 20 (n=43, 39, 82)1.9 ± 3.131.8 ± 2.541.9 ± 2.84
Week 28 (n=43, 39, 82)1.7 ± 2.662.9 ± 3.682.3 ± 3.23
Week 40 (n=41, 38, 79)1.8 ± 2.812.3 ± 4.112.0 ± 3.48
Week 52 (n=39, 32, 71)1.6 ± 2.422.2 ± 4.001.9 ± 3.22
SecondaryChange From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score

36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

Time frame:
Week (W) 16, 28, 52
Reported as:
Mean · Units on a scale
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
W16: Physical Functioning Domain (n=43, 40, 83)1.951 ± 5.18804.809 ± 9.18223.329 ± 7.4800
W16: Role-Physical Domain (n=43, 40, 83)6.160 ± 9.36155.130 ± 11.16005.664 ± 10.2172
W16: Bodily Pain Domain (n=43, 40, 83)11.808 ± 13.843110.663 ± 12.293611.256 ± 13.0524
W16: General Health Domain (n=43, 40, 83)2.392 ± 7.09334.333 ± 7.01453.328 ± 7.0799
W16: Vitality Domain (n=43, 40, 83)4.664 ± 9.54063.517 ± 11.44214.112 ± 10.4509
W16: Social Function Domain (n=43, 40, 83)7.629 ± 9.97347.932 ± 8.86457.775 ± 9.3992
W16: Role-Emotional Domain (n=43, 40, 83)7.219 ± 11.58985.584 ± 11.56546.431 ± 11.5365
W16: Mental Health Domain (n=43, 40, 83)5.928 ± 12.87575.125 ± 13.36135.541 ± 13.0378
W28: Physical Functioning Domain (n=43, 39, 82)1.571 ± 6.34464.303 ± 10.36952.870 ± 8.5558
W28: Role-Physical Domain (n=43, 39, 82)5.882 ± 10.63755.017 ± 11.46715.471 ± 10.9795
W28: Bodily Pain Domain (n=43, 39, 82)10.113 ± 15.94858.394 ± 12.54059.295 ± 14.3670
W28: General Health Domain (n=43, 39, 82)2.644 ± 5.92303.517 ± 7.13753.059 ± 6.5025
W28: Vitality Domain (n=43, 39, 82)4.038 ± 10.01163.608 ± 10.07423.833 ± 9.9815
W28: Social Function Domain (n=43, 39, 82)6.628 ± 11.30686.205 ± 10.43476.427 ± 10.8358
W28: Role-Emotional Domain (n=43, 39, 82)7.395 ± 11.88466.310 ± 12.95046.879 ± 12.3375
W28: Mental Health Domain (n=43, 39, 82)6.701 ± 12.43755.328 ± 12.81296.048 ± 12.5580
W52: Physical Functioning Domain (n=39,32,71)2.151 ± 5.61343.773 ± 7.35332.882 ± 6.4585
W52: Role-Physical Domain (n=39, 32, 71)6.669 ± 10.05204.623 ± 9.73405.747 ± 9.8926
W52: Bodily Pain Domain (n=39, 32, 71)12.335 ± 12.141310.673 ± 9.712811.586 ± 11.0678
W52: General Health Domain (n=39, 32, 71)2.758 ± 6.08664.888 ± 6.82353.718 ± 6.4707
W52: Vitality Domain (n=39, 32, 71)4.068 ± 10.56125.052 ± 8.51604.511 ± 9.6390
W52: Social Function Domain (n=39, 32, 71)8.411 ± 9.45988.402 ± 9.25778.407 ± 9.3024
W52: Role-Emotional Domain (n=39, 32, 71)8.445 ± 11.00185.915 ± 10.30917.305 ± 10.6949
W52: Mental Health Domain (n=39, 32, 71)7.317 ± 11.62436.926 ± 12.68617.141 ± 12.0276
SecondaryChange From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score

36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

Time frame:
Week 16, 28, 52
Reported as:
Mean · Units on a scale
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 16: Physical Health Score (n=43, 40, 83)4.719 ± 6.68066.146 ± 8.51925.407 ± 7.6087
Week 16: Mental Health Score (n=43, 40, 83)6.767 ± 11.09455.029 ± 11.49675.929 ± 11.2548
Week 28: Physical Health Score (n=43, 39, 82)3.770 ± 7.78294.799 ± 8.88934.259 ± 8.2914
Week 28: Mental Health Score (n=43, 39, 82)7.085 ± 11.36605.364 ± 10.90896.266 ± 11.1159
Week 52: Physical Health Score (n=39, 32, 71)4.676 ± 5.74055.250 ± 5.76144.935 ± 5.7159
Week 52: Mental Health Score (n=39, 32, 71)7.878 ± 10.19836.826 ± 10.59887.404 ± 10.3192
SecondaryWork Limitation Questionnaire (WLQ)

WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).

Time frame:
Baseline (BL), Week (W) 4, 16, 28, 52
Reported as:
Mean · Units on a scale
Work Limitation Questionnaire (WLQ)
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
BL: Time Management scale (n=34, 37, 71)44.49 ± 37.78342.36 ± 33.71643.38 ± 35.479
BL: Physical Demands scale (n=33, 35, 68)66.67 ± 33.52278.40 ± 31.12272.71 ± 32.606
BL: Mental/Interpersonal Demands Scale(n=34,38,72)28.61 ± 29.01231.52 ± 30.93030.15 ± 29.865
BL: Output Demands scale (n=33, 37, 70)22.61 ± 26.83230.27 ± 35.29526.66 ± 31.602
BL: WLQ Index Score (n=34, 38, 72)9.55 ± 6.71610.74 ± 8.04510.18 ± 7.420
W4: Time Management scale (n=31, 36, 67)35.32 ± 42.42531.39 ± 36.71533.21 ± 39.203
W4: Physical Demands scale (n=29, 36, 65)77.16 ± 33.01383.59 ± 29.59380.72 ± 31.083
W4:Mental/Interpersonal Demands Scale(n=32,36,68)17.94 ± 26.97923.39 ± 32.87820.82 ± 30.149
W4: Output Demands scale (n=30, 36, 66)13.50 ± 21.97820.14 ± 33.30617.12 ± 28.704
W4: WLQ Index Score (n=32, 37, 69)7.23 ± 5.5918.66 ± 7.7548.00 ± 6.827
W16: Time Management scale (n=31, 35, 66)35.07 ± 38.89433.29 ± 39.18234.12 ± 38.756
W16: Physical Demands scale (n=30, 32, 62)81.60 ± 26.98286.52 ± 25.54884.14 ± 26.153
W16:Mental/Interpersonal Demands Scale(n=31,35,66)13.33 ± 21.03820.28 ± 33.41917.01 ± 28.296
W16: Output Demands scale (n=32, 33, 65)11.88 ± 20.11119.55 ± 32.48515.77 ± 27.175
W16: WLQ Index Score (n=32, 35, 67)6.88 ± 4.7158.35 ± 7.4257.65 ± 6.276
W28: Time Management scale (n=34, 34, 68)38.68 ± 40.10029.78 ± 39.09234.23 ± 39.557
W28: Physical Demands scale (n=32, 34, 66)76.02 ± 31.04185.42 ± 24.73080.86 ± 28.151
W28:Mental/Interpersonal Demands Scale(n=33,35,68)16.84 ± 28.24216.39 ± 27.73616.61 ± 27.774
W28: Output Demands scale (n=33, 34, 67)13.94 ± 27.40814.71 ± 28.76114.33 ± 27.892
W28: WLQ Index Score (n=34, 36, 70)7.43 ± 6.4937.26 ± 6.8297.34 ± 6.620
W52: Time Management scale (n=31, 31, 62)50.32 ± 43.68331.88 ± 40.68641.10 ± 42.883
W52: Physical Demands scale (n=29, 29, 58)78.16 ± 30.20589.74 ± 24.41083.95 ± 27.838
W52:Mental/Interpersonal Demands Scale(n=30,30,60)25.56 ± 36.00716.89 ± 27.29321.22 ± 31.977
W52: Output Demands scale (n=30, 29, 59)22.63 ± 33.75012.24 ± 24.58917.52 ± 29.813
W52: WLQ Index Score (n=32, 31, 63)9.44 ± 8.1277.34 ± 6.4298.41 ± 7.358
SecondaryPercentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).

Time frame:
Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Baseline: Clear000
Baseline: Almost Clear000
Baseline: Mild02.31.1
Baseline: Moderate41.943.242.5
Baseline: Severe58.154.556.3
Week 2: Clear000
Week 2: Almost Clear2.301.1
Week 2: Mild2.329.516.1
Week 2: Moderate60.536.448.3
Week 2: Severe34.934.134.5
Week 4: Clear (n=43, 43, 86)02.31.2
Week 4: Almost Clear (n=43, 43, 86)4.79.37.0
Week 4: Mild (n=43, 43, 86)18.625.622.1
Week 4: Moderate (n=43, 43, 86)53.548.851.2
Week 4: Severe (n=43, 43, 86)23.314.018.6
Week 8: Clear (n=43, 41, 84)4.77.36.0
Week 8: Almost Clear (n=43, 41, 84)14.017.115.5
Week 8: Mild (n=43, 41, 84)32.634.133.3
Week 8: Moderate (n=43, 41, 84)39.534.136.9
Week 8: Severe (n=43, 41, 84)9.37.38.3
Week 12: Clear (n=43, 41, 84)2.37.34.8
Week 12: Almost Clear (n=43, 41, 84)20.926.823.8
Week 12: Mild (n=43, 41, 84)34.941.538.1
Week 12: Moderate (n=43, 41, 84)34.917.126.2
Week 12: Severe (n=43, 41, 84)7.07.37.1
Week 16: Clear (n=43, 40, 83)4.710.07.2
Week 16: Almost Clear (n=43, 40, 83)32.622.527.7
Week 16: Mild (n=43, 40, 83)23.335.028.9
Week 16: Moderate (n=43, 40, 83)32.622.527.7
Week 16: Severe (n=43, 40, 83)7.010.08.4
Week 20: Clear (n=43, 39, 82)7.012.89.8
Week 20: Almost Clear (n=43, 39, 82)37.223.130.5
Week 20: Mild (n=43, 39, 82)25.633.329.3
Week 20: Moderate (n=43, 39, 82)23.325.624.4
Week 20: Severe (n=43, 39, 82)7.05.16.1
Week 28: Clear (n=43, 39, 82)11.65.18.5
Week 28: Almost Clear (n=43, 39, 82)37.235.936.6
Week 28: Mild (n=43, 39, 82)23.320.522.0
Week 28: Moderate (n=43, 39, 82)20.933.326.8
Week 28: Severe (n=43, 39, 82)7.05.16.1
Week 40: Clear (n=41, 38, 79)7.318.412.7
Week 40: Almost Clear (n=41, 38, 79)46.331.639.2
Week 40: Mild (n=41, 38, 79)19.518.419.0
Week 40: Moderate (n=41, 38, 79)22.026.324.1
Week 40: Severe (n=41, 38, 79)4.95.35.1
Week 52: Clear (n=39, 32, 71)20.518.819.7
Week 52: Almost Clear (n=39, 32, 71)20.531.325.4
Week 52: Mild (n=39, 32, 71)28.225.026.8
Week 52: Moderate (n=39, 32, 71)15.421.918.3
Week 52: Severe (n=39, 32, 71)15.43.19.9
SecondaryJoint Pain Assessment (JPA)

The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain."

Time frame:
Baseline, Week 4, 16, 28, 52
Reported as:
Mean · Units on a scale
Joint Pain Assessment (JPA)
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Baseline5.25 ± 3.3274.60 ± 2.5584.83 ± 2.790
Week 4 (n=8, 14, 22)4.00 ± 2.7261.36 ± 1.0082.32 ± 2.191
Week 16 (n=8, 15, 23)1.88 ± 2.2950.60 ± 0.7371.04 ± 1.551
Week 28 (n=8, 14, 22)1.75 ± 1.7530.86 ± 0.9491.18 ± 1.332
Week 52 (n=4, 13, 17)0.50 ± 0.5770.54 ± 0.6600.53 ± 0.624
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response

ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Time frame:
Week 2, 4, 8, 12, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 20.062.541.7
Week 450.075.066.7
Week 875.010091.7
Week 1210087.591.7
Week 2010087.591.7
Week 28100100100
Week 4075.010091.7
Week 5250.010083.3
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response

ACR50 response: greater than or equal to (\>=) 50 percent (%) improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 20.025.016.7
Week 425.050.041.7
Week 850.062.558.3
Week 1275.075.075.0
Week 1675.087.583.3
Week 2010087.591.7
Week 2810075.083.3
Week 4075.087.583.3
Week 5250.087.575.0
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response

ACR70 response: greater than or equal to (\>=) 70 percent (%) improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Percentage of participantsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 20.00.00.0
Week 40.037.525.0
Week 825.062.550.0
Week 1250.062.558.3
Week 1650.062.558.3
Week 2075.075.075.0
Week 2875.050.058.3
Week 4050.075.066.7
Week 5250.075.066.7
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count

Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Tender/painful joints
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count
Tender/painful jointsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-1.8 ± 1.50-3.5 ± 2.78-2.9 ± 2.50
Week 4-6.3 ± 6.70-9.3 ± 11.37-8.3 ± 9.84
Week 8-11.5 ± 10.08-11.6 ± 10.24-11.6 ± 9.72
Week 12-13.8 ± 10.78-12.5 ± 11.95-12.9 ± 11.09
Week 16-13.0 ± 9.59-13.0 ± 12.17-13.0 ± 10.92
Week 20-14.3 ± 9.11-12.4 ± 12.87-13.0 ± 11.35
Week 28-14.0 ± 9.38-12.4 ± 12.52-12.9 ± 11.16
Week 40-14.3 ± 10.14-13.4 ± 12.09-13.7 ± 11.02
Week 52 (n=3, 8, 11)-11.3 ± 9.24-13.5 ± 12.08-12.9 ± 10.97
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count

Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Swollen joints
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count
Swollen jointsCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-1.8 ± 2.22-3.8 ± 5.55-3.1 ± 4.68
Week 4-5.0 ± 4.69-5.3 ± 5.80-5.2 ± 5.24
Week 8-6.0 ± 7.35-6.4 ± 4.37-6.3 ± 5.19
Week 12-6.5 ± 6.35-7.0 ± 4.44-6.8 ± 4.86
Week 16-7.3 ± 7.85-7.8 ± 3.85-7.6 ± 5.12
Week 20-7.0 ± 8.00-8.9 ± 4.42-8.3 ± 5.55
Week 28-7.3 ± 7.85-7.6 ± 4.03-7.5 ± 5.21
Week 40-7.3 ± 7.85-8.8 ± 4.20-8.3 ± 5.34
Week 52 (n=3, 8, 11)-3.0 ± 0.00-8.8 ± 4.13-7.2 ± 4.38
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain

Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-13.3 ± 8.30-29.5 ± 23.40-24.1 ± 20.77
Week 4-13.0 ± 23.41-41.4 ± 25.29-31.9 ± 27.42
Week 8-16.0 ± 19.78-43.6 ± 22.68-34.4 ± 24.88
Week 12-34.5 ± 19.71-46.0 ± 23.42-42.2 ± 22.07
Week 16-27.3 ± 15.22-46.0 ± 22.44-39.8 ± 21.65
Week 20-44.0 ± 22.82-45.3 ± 21.53-44.8 ± 20.91
Week 28-45.8 ± 23.26-45.8 ± 20.46-45.8 ± 20.34
Week 40-20.0 ± 54.86-46.9 ± 22.66-37.9 ± 36.37
Week 52 (n=3, 8, 11)-33.0 ± 31.19-48.4 ± 22.14-44.2 ± 24.28
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis

Subjects answered the following question, "Considering the possible effects of the arthritis, how are you feeling today?" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-8.0 ± 8.87-32.6 ± 27.55-24.4 ± 25.53
Week 4-20.5 ± 11.27-43.4 ± 27.47-35.8 ± 25.33
Week 8-23.3 ± 19.69-51.3 ± 20.53-41.9 ± 23.75
Week 12-45.0 ± 8.83-52.1 ± 21.35-49.8 ± 17.99
Week 16-40.0 ± 13.64-53.0 ± 20.96-48.7 ± 19.27
Week 20-49.5 ± 20.09-49.6 ± 20.26-49.6 ± 19.27
Week 28-52.3 ± 11.18-46.3 ± 26.67-48.3 ± 22.26
Week 40-20.8 ± 30.24-50.8 ± 20.78-40.8 ± 27.24
Week 52 (n=3, 8, 11)-40.7 ± 16.80-55.3 ± 20.51-51.3 ± 19.94
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis

The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-15.3 ± 18.01-28.5 ± 18.60-24.1 ± 18.74
Week 4-32.5 ± 22.28-34.6 ± 19.39-33.9 ± 19.38
Week 8-29.5 ± 30.01-41.8 ± 21.87-37.7 ± 24.21
Week 12-39.8 ± 21.00-45.8 ± 22.76-43.8 ± 21.42
Week 16-49.8 ± 23.34-47.9 ± 20.09-48.5 ± 20.16
Week 20-50.8 ± 25.29-45.3 ± 26.81-47.1 ± 25.28
Week 28-49.5 ± 25.96-42.8 ± 22.79-45.0 ± 22.92
Week 40-38.5 ± 39.03-49.5 ± 18.54-45.8 ± 25.76
Week 52 (n=3, 8, 11)-29.0 ± 20.30-46.8 ± 25.08-41.9 ± 24.32
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)

The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · mg/dL
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)
mg/dLCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-1.20 ± 2.137-1.68 ± 2.231-1.52 ± 2.114
Week 4-1.20 ± 2.267-1.69 ± 2.272-1.53 ± 2.178
Week 8-1.28 ± 2.354-1.70 ± 2.222-1.56 ± 2.167
Week 12-1.28 ± 2.351-1.68 ± 2.235-1.54 ± 2.174
Week 16-1.30 ± 2.337-1.69 ± 2.189-1.56 ± 2.139
Week 20-1.33 ± 2.387-1.59 ± 2.336-1.50 ± 2.246
Week 28-1.30 ± 2.337-1.15 ± 2.770-1.20 ± 2.526
Week 40 (n=4, 7, 11)-1.15 ± 2.037-1.84 ± 2.461-1.59 ± 2.236
Week 52 (n=3, 8, 11)-0.03 ± 0.058-1.65 ± 2.295-1.21 ± 2.064
SecondaryChange From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

Time frame:
Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Reported as:
Mean · Units on a scale
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)
Units on a scaleCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Week 2-0.19 ± 0.239-0.28 ± 0.376-0.25 ± 0.329
Week 4-0.28 ± 0.329-0.36 ± 0.381-0.33 ± 0.351
Week 8-0.28 ± 0.359-0.42 ± 0.433-0.38 ± 0.399
Week 12-0.28 ± 0.359-0.42 ± 0.433-0.38 ± 0.399
Week 16-0.31 ± 0.375-0.42 ± 0.433-0.39 ± 0.400
Week 20-0.28 ± 0.359-0.42 ± 0.433-0.38 ± 0.399
Week 28-0.34 ± 0.400-0.42 ± 0.433-0.40 ± 0.405
Week 40-0.09 ± 0.640-0.42 ± 0.433-0.31 ± 0.507
Week 52 (n=3, 8, 11)-0.13 ± 0.573-0.42 ± 0.433-0.34 ± 0.465

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 5 mg BID—3/47 (6.4%)37/47 (78.7%)
CP-690,550 10 mg BID—3/47 (6.4%)40/47 (85.1%)
Total—6/94 (6.4%)77/94 (81.9%)
Most frequent serious events
Most frequent serious events
EventCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Herpes zosterInfections and infestations3/470/473/94
VertigoEar and labyrinth disorders0/471/471/94
ImpetigoInfections and infestations0/471/471/94
Erythrodermic psoriasisSkin and subcutaneous tissue disorders0/471/471/94
PsoriasisSkin and subcutaneous tissue disorders0/471/471/94
Most frequent other events
Showing 10 of 115
Most frequent other events
EventCP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
NasopharyngitisInfections and infestations14/4714/4728/94
Herpes zosterInfections and infestations3/4710/4713/94
Tinea pedisInfections and infestations4/476/4710/94
PsoriasisSkin and subcutaneous tissue disorders4/476/4710/94
Haemoglobin decreasedInvestigations1/474/475/94
Dental cariesGastrointestinal disorders3/471/474/94
PyrexiaGeneral disorders0/473/473/94
GastroenteritisInfections and infestations3/470/473/94
InfluenzaInfections and infestations3/473/476/94
Alanine aminotransferase increasedInvestigations1/473/474/94

Baseline characteristics

Age, Continuous
Age, Continuous(years)CP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Mean50.9 ± 11.846.4 ± 10.848.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 5 mg BIDCP-690,550 10 mg BIDTotal
Female8816
Male393978
09

Study locations

16 sites
  • JR Sapporo hospital
    Sapporo, Hokkaido 060-0033, Japan
  • Kobe University Hospital
    Chuo-ku, Kobe, Hyogo 650-0017, Japan
  • Kanazawa Medical University Hospital
    Kahoku-gun, Ishikawa 920-0293, Japan
  • National Hospital Organization Sagamihara National Hospital
    Sagamihara, Kanagawa 252-0392, Japan
  • University of Miyazaki Hospital
    Miyazaki-shi, Miyazaki 889-1692, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 324-0498, Japan
  • Tokyo Teishin Hospital
    Chiyoda-ku, Tokyo 102-8798, Japan
  • Tokyo medical university Hachioji medical center
    Hachioji, Tokyo 193-0998, Japan
  • Kanto Medical Center NTT East Corporation
    Shinagawa-ku, Tokyo 141-8625, Japan
  • Tokyo Medical University Hospital
    Shinjyuku-ku, Tokyo 160-0023, Japan
  • Tonami General Hospital
    Tonami, Toyama 939-1395, Japan
  • Yamanashi Prefectural Central Hospital
    Kofu, Yamanashi 400-8506, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
  • Nissay Hospital
    Osaka, 550-0012, Japan
  • Jikei University Hospital
    Tokyo, 105-8471, Japan
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2011
First posted
Jan 26, 2012
Start
Mar 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Aug 13, 2015
Last update
Aug 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01519089
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 26, 2012
Start date
Mar 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Aug 13, 2015
Last update
Aug 13, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion